loading

왜 Aclaris Therapeutics Inc (ACRS) 주가가 하락하고 있습니까?

2024-11-20 거래 세션 동안 Aclaris Therapeutics Inc(ACRS) 주식이 13.73% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
diagnostics_research LH
$239.53
price up icon 0.74%
$170.39
price up icon 1.49%
$130.78
price down icon 0.68%
diagnostics_research WAT
$366.26
price up icon 2.36%
diagnostics_research MTD
$1,186.88
price up icon 1.66%
$408.36
price down icon 1.66%
자본화:     |  볼륨(24시간):